Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Personalized Tumor Neoantigen Based Vaccine FRAME-001 for Advanced Non-Small Cell Lung Cancer

NCT04998474 is registered in ClinicalTrials.gov with Frame Pharmaceuticals B.V. as lead sponsor.

NCT NCT04998474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04998474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Personalized Tumor Neoantigen Based Vaccine FRAME-001 for Advanced Non-Small Cell Lung Cancer
Lead sponsor
Frame Pharmaceuticals B.V.
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2022
Completion date
July 31, 2024
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer